IQVIA (NYSE:IQV) Price Target Raised to $288.00 at JPMorgan Chase & Co.

IQVIA (NYSE:IQV) had its price target lifted by JPMorgan Chase & Co. from $260.00 to $288.00 in a research report sent to investors on Monday, Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other equities analysts have also weighed in on IQV. Truist Financial boosted their price objective on shares of IQVIA from $292.00 to $300.00 and gave the company a buy rating in a research report on Tuesday, July 23rd. Robert W. Baird boosted their price objective on shares of IQVIA from $235.00 to $251.00 and gave the company a neutral rating in a research report on Tuesday, July 23rd. Argus raised shares of IQVIA to a strong-buy rating in a research report on Wednesday, July 31st. Barclays upped their price target on shares of IQVIA from $255.00 to $275.00 and gave the stock an overweight rating in a research report on Tuesday, July 23rd. Finally, The Goldman Sachs Group assumed coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a buy rating and a $270.00 price target for the company. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $265.67.

IQVIA Price Performance

IQV traded up $3.61 during midday trading on Monday, reaching $237.26. 920,887 shares of the company’s stock were exchanged, compared to its average volume of 1,092,109. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The stock has a market capitalization of $43.23 billion, a PE ratio of 32.71, a P/E/G ratio of 2.35 and a beta of 1.49. The business’s 50-day moving average price is $221.85 and its 200 day moving average price is $230.78. IQVIA has a 1-year low of $167.42 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.22 earnings per share. As a group, equities analysts anticipate that IQVIA will post 10.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Team Hewins LLC boosted its stake in shares of IQVIA by 5.0% in the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 46 shares during the period. Covestor Ltd boosted its stake in shares of IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 48 shares during the period. Oregon Public Employees Retirement Fund boosted its stake in shares of IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after purchasing an additional 48 shares during the period. Jag Capital Management LLC raised its holdings in IQVIA by 0.4% in the fourth quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock valued at $2,638,000 after acquiring an additional 49 shares in the last quarter. Finally, Continuum Advisory LLC raised its holdings in IQVIA by 3.3% in the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 49 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.